Wall Street Zen Upgrades Envista (NYSE:NVST) to “Strong-Buy”

Envista (NYSE:NVSTGet Free Report) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Several other research analysts have also recently commented on the company. Piper Sandler reissued a “neutral” rating and set a $28.00 price target (up from $26.00) on shares of Envista in a research report on Thursday, August 6th. Mizuho set a $29.00 price objective on Envista in a research note on Thursday, August 6th. Robert W. Baird set a $34.00 price objective on Envista in a research note on Thursday, August 6th. Evercore reissued an “outperform” rating and issued a $33.00 price objective on shares of Envista in a report on Thursday, May 7th. Finally, JPMorgan Chase & Co. raised their target price on shares of Envista from $26.00 to $29.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Envista has a consensus rating of “Moderate Buy” and an average target price of $29.31.

Check Out Our Latest Research Report on Envista

Envista Stock Up 0.0%

Shares of NVST stock opened at $27.21 on Friday. The firm’s fifty day moving average price is $26.90 and its two-hundred day moving average price is $26.30. The company has a current ratio of 2.43, a quick ratio of 2.07 and a debt-to-equity ratio of 0.47. Envista has a 1 year low of $18.77 and a 1 year high of $30.42. The firm has a market capitalization of $4.37 billion, a P/E ratio of 46.91, a PEG ratio of 1.30 and a beta of 0.86.

Envista (NYSE:NVSTGet Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. The company had revenue of $730.50 million during the quarter, compared to the consensus estimate of $716.11 million. Envista had a net margin of 3.33% and a return on equity of 7.88%. The company’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 EPS. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. On average, equities analysts predict that Envista will post 1.53 EPS for the current fiscal year.

Institutional Trading of Envista

Institutional investors and hedge funds have recently bought and sold shares of the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Envista during the 2nd quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd raised its stake in Envista by 16,711.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after acquiring an additional 1,504 shares during the period. Allworth Financial LP raised its stake in Envista by 75.4% in the 4th quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock valued at $39,000 after acquiring an additional 776 shares during the period. Nykredit A S acquired a new stake in Envista during the 2nd quarter valued at $52,000. Finally, UMB Bank n.a. lifted its holdings in Envista by 46.1% during the 4th quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock valued at $44,000 after purchasing an additional 636 shares during the last quarter.

Envista Company Profile

(Get Free Report)

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.

See Also

Analyst Recommendations for Envista (NYSE:NVST)

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.